These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

451 related items for PubMed ID: 23602523

  • 1. The discovery of colchicine-SAHA hybrids as a new class of antitumor agents.
    Zhang X, Zhang J, Tong L, Luo Y, Su M, Zang Y, Li J, Lu W, Chen Y.
    Bioorg Med Chem; 2013 Jun 01; 21(11):3240-4. PubMed ID: 23602523
    [Abstract] [Full Text] [Related]

  • 2. Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors.
    Zhang X, Kong Y, Zhang J, Su M, Zhou Y, Zang Y, Li J, Chen Y, Fang Y, Zhang X, Lu W.
    Eur J Med Chem; 2015 May 05; 95():127-35. PubMed ID: 25805446
    [Abstract] [Full Text] [Related]

  • 3. Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
    Oanh DT, Hai HV, Park SH, Kim HJ, Han BW, Kim HS, Hong JT, Han SB, Hue VT, Nam NH.
    Bioorg Med Chem Lett; 2011 Dec 15; 21(24):7509-12. PubMed ID: 22036991
    [Abstract] [Full Text] [Related]

  • 4. New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
    Tazzari V, Cappelletti G, Casagrande M, Perrino E, Renzi L, Del Soldato P, Sparatore A.
    Bioorg Med Chem; 2010 Jun 15; 18(12):4187-94. PubMed ID: 20576572
    [Abstract] [Full Text] [Related]

  • 5. Synthesis and antitumor activity of novel diaryl ether hydroxamic acids derivatives as potential HDAC inhibitors.
    Zhu Y, Chen X, Wu Z, Zheng Y, Chen Y, Tang W, Lu T.
    Arch Pharm Res; 2012 Oct 15; 35(10):1723-32. PubMed ID: 23139122
    [Abstract] [Full Text] [Related]

  • 6. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
    Guan P, Sun F, Hou X, Wang F, Yi F, Xu W, Fang H.
    Bioorg Med Chem; 2012 Jun 15; 20(12):3865-72. PubMed ID: 22579621
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next.
    Thaler F, Mercurio C.
    ChemMedChem; 2014 Mar 15; 9(3):523-6. PubMed ID: 24730063
    [Abstract] [Full Text] [Related]

  • 12. Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.
    Chetan B, Bunha M, Jagrat M, Sinha BN, Saiko P, Graser G, Szekeres T, Raman G, Rajendran P, Moorthy D, Basu A, Jayaprakash V.
    Bioorg Med Chem Lett; 2010 Jul 01; 20(13):3906-10. PubMed ID: 20605448
    [Abstract] [Full Text] [Related]

  • 13. Synthesis and biological characterization of amidopropenyl hydroxamates as HDAC inhibitors.
    Thaler F, Varasi M, Colombo A, Boggio R, Munari D, Regalia N, Rozio MG, Reali V, Resconi AE, Mai A, Gagliardi S, Dondio G, Minucci S, Mercurio C.
    ChemMedChem; 2010 Aug 02; 5(8):1359-72. PubMed ID: 20572281
    [Abstract] [Full Text] [Related]

  • 14. 2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
    Mahboobi S, Sellmer A, Höcher H, Garhammer C, Pongratz H, Maier T, Ciossek T, Beckers T.
    J Med Chem; 2007 Sep 06; 50(18):4405-18. PubMed ID: 17691763
    [Abstract] [Full Text] [Related]

  • 15. Design, synthesis and biological evaluation of tyrosine-based hydroxamic acid analogs as novel histone deacetylases (HDACs) inhibitors.
    Zhang Y, Feng J, Liu C, Fang H, Xu W.
    Bioorg Med Chem; 2011 Aug 01; 19(15):4437-44. PubMed ID: 21733698
    [Abstract] [Full Text] [Related]

  • 16. Novel HDAC/Tubulin Dual Inhibitor: Design, Synthesis and Docking Studies of α-Phthalimido-Chalcone Hybrids as Potential Anticancer Agents with Apoptosis-Inducing Activity.
    Mourad AAE, Mourad MAE, Jones PG.
    Drug Des Devel Ther; 2020 Aug 01; 14():3111-3130. PubMed ID: 32848361
    [Abstract] [Full Text] [Related]

  • 17. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
    Cai J, Wei H, Hong KH, Wu X, Cao M, Zong X, Li L, Sun C, Chen J, Ji M.
    Eur J Med Chem; 2015 Aug 01; 96():1-13. PubMed ID: 25874326
    [Abstract] [Full Text] [Related]

  • 18. Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors.
    Zhang Y, Feng J, Liu C, Zhang L, Jiao J, Fang H, Su L, Zhang X, Zhang J, Li M, Wang B, Xu W.
    Bioorg Med Chem; 2010 Mar 01; 18(5):1761-72. PubMed ID: 20171895
    [Abstract] [Full Text] [Related]

  • 19. Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors.
    Liu R, Wang J, Tang W, Fang H.
    Bioorg Med Chem; 2016 Apr 01; 24(7):1446-54. PubMed ID: 26907204
    [Abstract] [Full Text] [Related]

  • 20. Improved antiproliferative activity of 1,3,4-thiadiazole-containing histone deacetylase (HDAC) inhibitors by introduction of the heteroaromatic surface recognition motif.
    Guan P, Wang L, Hou X, Wan Y, Xu W, Tang W, Fang H.
    Bioorg Med Chem; 2014 Nov 01; 22(21):5766-75. PubMed ID: 25311567
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.